Serum iron (SI), total iron binding capacity (TIBC), and transferrin saturation (TS) by treatment in mice chronically treated with DOX
Treatment . | SI, μM . | TIBC, μM . | TS, % . |
---|---|---|---|
Wild-type | |||
Saline | 21.4 ± 2.9 | 47.6 ± 4.4 | 45.0 ± 6.2 |
DOX | |||
Survivors | 26.2 ± 4.9 | 47.2 ± 2.8 | 55.1 ± 9.7 |
Nonsurvivors | 30.5 ± 6.8* | 33.3 ± 10.6* | 93.0 ± 9.3* |
Hfe+/− | |||
Saline | 31.9 ± 4.3† | 46.1 ± 1.8 | 67.0 ± 9.0† |
DOX | |||
Survivors | 25.8 ± 2.9 | 47.8 ± 3.7 | 54.0 ± 8.0 |
Nonsurvivors | 30.6 ± 6.8 | 33.4 ± 5.8* | 94.5 ± 18.0* |
Hfe−/− | |||
Saline | 41.5 ± 3.7† | 42.4 ± 2.1‡ | 98.0 ± 7.4† |
DOX | |||
Survivors | 39.3 ± 8.3 | 41.3 ± 7.4‡ | 95.0 ± 7.7 |
Nonsurvivors | 36.3 ± 10.2 | 36.6 ± 10.0 | 99.5 ± 8.1 |
Treatment . | SI, μM . | TIBC, μM . | TS, % . |
---|---|---|---|
Wild-type | |||
Saline | 21.4 ± 2.9 | 47.6 ± 4.4 | 45.0 ± 6.2 |
DOX | |||
Survivors | 26.2 ± 4.9 | 47.2 ± 2.8 | 55.1 ± 9.7 |
Nonsurvivors | 30.5 ± 6.8* | 33.3 ± 10.6* | 93.0 ± 9.3* |
Hfe+/− | |||
Saline | 31.9 ± 4.3† | 46.1 ± 1.8 | 67.0 ± 9.0† |
DOX | |||
Survivors | 25.8 ± 2.9 | 47.8 ± 3.7 | 54.0 ± 8.0 |
Nonsurvivors | 30.6 ± 6.8 | 33.4 ± 5.8* | 94.5 ± 18.0* |
Hfe−/− | |||
Saline | 41.5 ± 3.7† | 42.4 ± 2.1‡ | 98.0 ± 7.4† |
DOX | |||
Survivors | 39.3 ± 8.3 | 41.3 ± 7.4‡ | 95.0 ± 7.7 |
Nonsurvivors | 36.3 ± 10.2 | 36.6 ± 10.0 | 99.5 ± 8.1 |